Fox Chase Cancer Center's Dr. Karanicolas to Join the School of Pharmacy as the Director of the Moulder Center
The Temple University School of Pharmacy is pleased to announce the appointment of John Karanicolas, PhD as the Director of the Moulder Center for Drug Discovery Research effective January 1, 2022.
In this role, Dr. Karanicolas will:
- Lead the development of novel drug candidates using state-of the art drug discovery approaches and cutting-edge science
- Foster collaborative research within Temple University and outside universities, research institutions, pharmaceutical and biotech companies, and more
- Advance translational medicine initiatives by bridging the gap between pre-clinical and clinical research
- Mentor the development of faculty members pursuing vigorous, independent research programs focused on target identification, target validation, and development of new therapeutic candidates
Dr. Karanicolas will continue to hold his role as Professor of Molecular Therapeutics at Fox Chase Cancer Center. He will also continue his adjunct appointments in the Department of Medical Genetics and Molecular Biochemistry at the Lewis Katz School of Medicine and in the Department of Bioengineering at Temple University, as well as in the Department of Biochemistry and Biophysics at the University of Pennsylvania.
In his candidate presentation, Dr. Karanicolas discussed “Designing new therapeutic modalities using computational chemical biology” and how he will apply these innovations to the critical drug discovery work at the Moulder Center. He will build upon his abundance of research and lead the Moulder Center into its next phase of growth during his three-year term.